1-苄基-5-羟甲基-1H-咪唑 | 80304-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-苄基-5-羟甲基-1H-咪唑
• 中文别名: 呋喃菲林
• 英文名称: 1-benzyl-5-hydroxymethylimidazole
• 英文别名: 1-Benzyl-5-hydroxymethyl-imidazole；N¹-Benzyl-5-hydroxymethylimidazole；1-Benzyl-5-(hydroxymethyl)-1H-imidazole；4-(1-benzyl-1H-imidazol-5-yl)methanol；[(1-benzyl-1H)-imidazol-5-yl]methanol；1-benzyl-1H-5-hydroxymethylimidazole；1-Benzyl-5-hydroxymethyl-1h-imidazole；(3-benzylimidazol-4-yl)methanol
• CAS: 80304-50-3
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD02179524
• 分子量: 188.229
• InChiKey: GQZILHANXWXTIW-UHFFFAOYSA-N

物化性质

• 熔点：
  133-134°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• 安全说明：
  S26,S36/37/39
• WGK Germany：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Benzyl-5-hydroxymethyl-1H-imidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Benzyl-5-hydroxymethyl-1H-imidazole
CAS number: 80304-50-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H12N2O
Molecular weight: 188.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苄基-5-羟甲基-1H-咪唑 在 氯化亚砜 作用下， 反应 0.33h， 以99%的产率得到1-Benzyl-5-(chloromethyl)-1H-imidazolium chloride
  参考文献：
  名称：

  稳定同位素特异性标记的L-组氨酸的合成

  摘要：

  （2'- 13 C）-，（1'- 15 N）-和（3'- 15 N）-L-组氨酸是根据允许13 C或15对所有碳和氮位置或位置的任何组合进行N标记。通过将甲苯磺酰基甲基异氰化物与3-苯基丙烯醛缩合并随后环加苄胺来构建1，5-二取代的咪唑环。将咪唑中间体转化为1-苄基-5-（氯甲基）-咪唑鎓氯化物，其通过与环D-戊基甘氨酸的双内酯醚的对映选择性偶联而与甘氨酸部分偶联。偶联产物的脱保护得到高光学纯度的L-组氨酸。同位素标记的合成子的合成是从简单的，可商购的，高度富集的化合物开始的。通过质谱和1 H-，13 C-和15表征标记的L-组氨酸N-NMR光谱。

  DOI：

  10.1002/recl.19941130603
• 作为产物：
  描述：

  3-苄基-2-巯基-3,5-二氢-4H-咪唑-4-酮 在 lithium aluminium tetrahydride 、 硫酸 、 三氟化硼乙醚 、 硝酸 、 potassium carbonate 、 sodium nitrite 、 乙硫醇钠 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 乙腈 、 苯 为溶剂， 反应 43.42h， 生成 1-苄基-5-羟甲基-1H-咪唑
  参考文献：
  名称：

  从 13C-硫氰酸酯开始制备 2'-13C-L-组氨酸：合成获得任何定点稳定同位素富集的 L-组氨酸

  摘要：

  1-Benzyl-2-(methylthio)-imidazole-5-ketone 从硫氰酸盐和甘氨酸酰胺 (glycin) 开始，通过几个简单的步骤获得。随后用磷酸二乙酯和官能团处理进行处理，得到 1-苄基-5-氯甲基-咪唑鎓氯化物。该化合物在温和的 O'Donnell 条件下转化为相应的 L-组氨酸衍生物。脱保护后，L-组氨酸以良好的收率和 99% 的对映体过量获得。2'-13C-L-组氨酸已通过这种新方案获得，从市售的 13C-硫氰酸酯开始，13C 掺入率高 (99%)。这种合成方案允许获得 L-组氨酸的任何同位素和许多其他生物学上重要的咪唑衍生物。

  DOI：

  10.3390/molecules19011023

文献信息

• Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
  申请人：——

  公开号：US20020120011A1

  公开（公告）日：2002-08-29

  The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound: 1

  这项发明涉及替代多环芳基和杂环芳基的三级杂烷基胺化合物，可用作胆固醇酯转移蛋白（CETP；血浆脂质转移蛋白-I）的抑制剂，以及用于治疗动脉粥样硬化和其他冠状动脉疾病的化合物、组合物和方法。首选的三级杂烷基胺化合物是取代的N,N-二取代二胺。首选的具体N,N-二取代二胺化合物是：1
• [EN] TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE MYÉLOPEROXYDASE DE TYPE TRIAZOLOPYRIDINE ET TRIAZOLOPYRIMIDINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2016040417A1

  公开（公告）日：2016-03-17

  The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式（I）的化合物：其中A和R1如规范中所定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Synthesis of L-histidine specifically labelled with stable isotopes
  作者：J. J. Cappon、K. D. Witters、J. Baart、P. J. E. Verdegem、A. C. Hoek、R. J. H. Luiten、J. Raap、J. Lugtenburg

  DOI：10.1002/recl.19941130603

  日期：——

  coupling with the bislactim ether of cyclo-D-valylglycine. Deprotection of the coupling product afforded L-histidine in high optical purity. Syntheses for the isotopically labelled synthons were developed starting from simple, commercially available, highly enriched compounds. The labelled L-histidines were characterized by mass spectrometry and 1H-, 13C- and 15N-NMR spectroscopy.

  （2'- 13 C）-，（1'- 15 N）-和（3'- 15 N）-L-组氨酸是根据允许13 C或15对所有碳和氮位置或位置的任何组合进行N标记。通过将甲苯磺酰基甲基异氰化物与3-苯基丙烯醛缩合并随后环加苄胺来构建1，5-二取代的咪唑环。将咪唑中间体转化为1-苄基-5-（氯甲基）-咪唑鎓氯化物，其通过与环D-戊基甘氨酸的双内酯醚的对映选择性偶联而与甘氨酸部分偶联。偶联产物的脱保护得到高光学纯度的L-组氨酸。同位素标记的合成子的合成是从简单的，可商购的，高度富集的化合物开始的。通过质谱和1 H-，13 C-和15表征标记的L-组氨酸N-NMR光谱。
• AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2725024A1

  公开（公告）日：2014-04-30

  The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

  本发明涉及药物化学领域，特别是一种由一般式（I）、（II）或（III）表示的新型类唑化合物，以及其制备方法，以这些化合物为活性成分的药物组合物，以及在制备用于治疗与Lp-PLA2酶活性相关疾病的药物中使用这些唑化合物和药物组合物的用途，其中每个取代基如规范中所定义。
• Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase
  作者：Junko Ohkanda、Corey L. Strickland、Michelle A. Blaskovich、Dora Carrico、Jeffrey W. Lockman、Andreas Vogt、Cynthia J. Bucher、Jiazhi Sun、Yimin Qian、David Knowles、Erin E. Pusateri、Saïd M. Sebti、Andrew D. Hamilton

  DOI：10.1039/b508184j

  日期：——

  A series of imidazole-containing peptidomimetic PFTase inhibitors and their co-crystal structures bound to PFTase and FPP are reported. The structures reveal that the peptidomimetics adopt a similar conformation to that of the extended CVIM tetrapeptide, with the imidazole group coordinating to the catalytic zinc ion. Both mono- and bis-imidazole-containing derivatives, 13 and 16, showed remarkably high enzyme inhibition activity against PFTase in vitro with IC50 values of 0.86 and 1.7 nM, respectively. The peptidomimetics were also highly selective for PFTase over PGGTase-I both in vitro and in intact cells. In addition, peptidomimetics 13 and 16 were found to suppress tumor growth in nude mouse xenograft models with no gross toxicity at a daily dose of 25 mg kg−1.

  报道了一系列含有咪唑基的肽模拟物PFTase抑制剂及其与PFTase和FPP结合的共晶结构。这些结构揭示了肽模拟物采取类似于延伸的CVIM四肽的构象，其中的咪唑基团与催化锌离子配位。含有单咪唑和双咪唑的衍生物13和16，在体外分别表现出对PFTase极高的酶抑制活性，IC50值分别为0.86和1.7 nM。这些肽模拟物对PFTase的选择性优于PGGTase-I，无论是在体外还是在完整的细胞中。此外，肽模拟物13和16在裸鼠异种移植模型中能抑制肿瘤生长，以每天25 mg kg−1的剂量给药时没有明显的毒性。